Fluoroquinolones and nitrofurantoin have surpassed trimethoprim-sulfamethoxazole (TMP-SMZ) as the most frequently prescribed antibiotics for uncomplicated urinary tract infections (UTIs) in women, according to a new national analysis. This is despite well-established recommendations (from the Infectious Disease Society of America and others) that TMP-SMZ is the drug of choice for UTIs due to cost and concerns about antibiotic resistance.
A three-tier pharmacy benefit can reduce prescription drug spending without increasing other medical resource use or fueling medication discontinuation rates. So concludes the fully published report of an analysis whose preliminary results were presented last year and reported by Formulary (2001;36:522). It is the first well-designed, controlled study to explore such consequences of three-tier benefits.
Clinicians must use caution in adopting newly revised national guidelines for treating elevated cholesterol, concludes a new study from the University of Maryland Pharmaceutical Health Services Research Department.
FDA actions in brief as reported February 1, 2002
New combination: Fixed niacin/statin combination for second-line lipid
NME: Topical nonsteroid for second-line eczema Tx
NME: 5-alpha reductase inhibitor for treatmentof benign prostatic hyperplasia
NME: Loratadine successor for symptoms of seasonal allergic rhinitis
FDA Actions in Brief as reported January 1, 2002
The selective serotonin reuptake inhibitors (SSRIs) fluoxetine, sertraline,
and paroxetine are equally effective and tolerated in depressed patients
across a broad range of outcome measures. So finds an open-label, randomized
study in 573 patients treated for depression for 9 months in a primary care